Manipulation of skin graft rejection in alloimmune mice by anti-VCAM-1:VLA-4 but not anti-ICAM-1:LFA-1 monoclonal antibodies.
C3H mice were immunized by repeated skin grafting with B10.BR tail skin. Ten days after the last immunization mice received 100 micrograms (intravenously) of a variety of different monoclonal antibodies (mAbs: anti-ICAM-1, -LFA-1, -VCAM-1, -VLA-4), alone or in combination, followed by further B10.BR skin grafts. Control animals received injections of saline only. Skin graft survival was monitored daily in all groups. Further injections of antibody were given every second day until graft rejection occurred. In separate studies lymphoid cells were harvested from various tissues of the grafted mice at 6 and 20 days post grafting. Aliquots of each sample were analysed by polymerase chain reaction for mRNA for different cytokines (interleukins IL-2, IL-4, IL-10 and IFN gamma (gamma-interferon)) believed to be important in the regulation of graft rejection. In addition, lymphoid cells were restimulated in vitro with irradiated B10.BR or third-party stimulator cells in the presence or absence of monolayers of C3H-derived endothelial cells (EC), in an attempt to mimic the in vivo environment of the interactions of cells engaged in alloreactivity in these mice. Only anti-VCAM-1 caused significant prolongation of graft survival in immune mice, while in contrast only the combination of anti-ICAM-1 and anti-LFA-1 produced enhanced survival in naive animals. In each case increased survival was associated with decreased activation of Th1 cells (diminished IL-2, IFN gamma) and increased activation of Th2 cells (increased IL-4, IL-10).(ABSTRACT TRUNCATED AT 250 WORDS)
Gorcyznski
R M
RM
Department of Surgery, Toronto Hospital, Ontario, Canada.
Chung
S
S
Fu
X M
XM
Levy
G
G
Sullivan
B
B
Chen
Z
Z
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000627:therapeutic use*; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D004730:Endothelium, Vascular; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D039041:Integrin alpha4beta1; D016023:Integrins / Q000276:immunology; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D012333:RNA, Messenger / Q000096:biosynthesis; D016201:Receptors, Lymphocyte Homing / Q000276:immunology; D016038:Skin Transplantation; D019010:Vascular Cell Adhesion Molecule-1 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D039041:Integrin alpha4beta1; D016023:Integrins; D016169:Lymphocyte Function-Associated Antigen-1; D012333:RNA, Messenger; D016201:Receptors, Lymphocyte Homing; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1